GENETICALLY ENGINEERED BIOLOGICAL INDICATOR
    46.
    发明申请
    GENETICALLY ENGINEERED BIOLOGICAL INDICATOR 有权
    遗传工程生物学指标

    公开(公告)号:US20080070231A1

    公开(公告)日:2008-03-20

    申请号:US11533522

    申请日:2006-09-20

    CPC classification number: C12N15/75 C12N9/2471 C12Y302/01023

    Abstract: The disclosed technology relates to a genetically engineered biological indicator, comprising: at least one test organism and at least one reporter gene suitable for producing an indicator enzyme, the reporter gene being taken up by the test organism; and at least one repressor gene that inhibits expression of the reporter gene until the reporter gene is exposed to at least one inducer. A process and an apparatus for using the biological indicator are disclosed.

    Abstract translation: 所公开的技术涉及基因工程生物指示剂,其包含:至少一种测试生物体和至少一种适用于产生指示酶的报告基因,所述报道基因被测试生物体吸收; 以及抑制报告基因表达的至少一个抑制基因,直到报告基因暴露于至少一种诱导物。 公开了一种使用生物指示剂的方法和装置。

    Pharmacological vitreolysis
    47.
    发明申请

    公开(公告)号:US20080050356A1

    公开(公告)日:2008-02-28

    申请号:US11786250

    申请日:2007-04-11

    Abstract: Methods of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject, comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD) are disclosed. TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy.

Patent Agency Ranking